10-Q: Raphael Pharmaceutical Inc. Reports Increased R&D Spending and Net Loss in Q1 2024

Raphael Pharmaceutical Inc. reported a significant increase in research and development expenses and a larger net loss for the first quarter of 2024 compared to the same period last year.

Summary

• Raphael Pharmaceutical Inc. reported its financial results for the first quarter of 2024, showing a net loss of $550,000, which is an increase from the $264,000 loss in the same period of 2023.
• The company's research and development expenses significantly increased to $379,000, up from $114,000 in the first quarter of 2023, primarily due to progress in research activities with Rambam.
• General and administrative expenses also rose to $168,000, a $24,000 increase from the $144,000 reported in the first quarter of 2023, mainly due to higher professional service costs.
• The company's operating loss for the quarter was $547,000, compared to $258,000 in the same period last year.
• Raphael Pharmaceutical had no revenue in either the first quarter of 2024 or 2023.
• As of March 31, 2024, the company had $287,000 in cash and cash equivalents.
• The company has an accumulated deficit of $7,860,000 as of March 31, 2024.
• The company is currently in the pre-clinical development stage and has not yet generated revenues.
• The company is conducting a proof-of-concept clinical trial in the U.S. for its RA product candidate, with an estimated completion timeline of six months from the first patient recruitment.

Sentiment

Score: 3

Explanation: The document highlights significant losses, increased expenses, and a going concern warning, indicating a negative outlook. While there are some positive developments in clinical trials, the financial situation is concerning.

Positives

• The company has commenced a proof-of-concept clinical trial in the U.S. for its RA product candidate.
• The company has successfully completed pre-clinical studies on human-derived immune cells and mouse models for both COVID-19 and RA products.
• The company has secured additional funding through the issuance of shares and warrants.
• The company has a research agreement with Rambam Health Care Campus for the development of cannabinoid-based treatments.

Negatives

• The company's net loss increased significantly in Q1 2024 compared to Q1 2023.
• The company has not generated any revenue to date.
• The company's operating loss has more than doubled year-over-year.
• The company has an accumulated deficit of $7,860,000 as of March 31, 2024.
• The company's current cash on hand is not sufficient to fund projected operating requirements, raising substantial doubt about its ability to continue as a going concern.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash to fund operations.
• The company is dependent on raising additional capital to fund research and development, clinical trials, and commercialization efforts.
• There is no guarantee that the company will be able to obtain additional financing on acceptable terms or at all.
• The company is subject to risks associated with regulatory approvals, clinical trial outcomes, and market acceptance of its products.
• The company is in the pre-clinical development stage and has not yet generated revenues, making it a high-risk investment.

Future Outlook

The company anticipates needing approximately $800,000 for research and development and $850,000 for capital expenditures over the next 12 months and will require significant additional financing in the near future to fund its operations. The company expects to continue to generate losses from development, clinical development and regulatory activities.

Management Comments

• Management expects that the Company will continue to generate losses from the development, clinical development and regulatory activities of its product, which will result in negative cash flow from operating activity.
• Management has concluded that substantial doubt about the Company's ability to continue as a going concern exists in the event that additional funding does not occur.
• Management plans include raising capital in the United States.

Industry Context

The company is operating in the pharmaceutical industry, specifically focusing on cannabinoid-based therapies, which is a growing area of interest. The company's focus on inflammation-related conditions like rheumatoid arthritis and COVID-19 aligns with current medical needs and research trends.

Comparison to Industry Standards

• Compared to other early-stage pharmaceutical companies, Raphael's high R&D spending is typical as they are in the pre-clinical and early clinical trial phase.
• The lack of revenue is also common for companies at this stage, as they are focused on research and development rather than commercialization.
• The company's reliance on external funding is consistent with industry norms for biotech startups, which often require significant capital to advance their drug candidates.
• The company's focus on cannabinoid-based therapies is a niche area within the pharmaceutical industry, with a few other companies such as GW Pharmaceuticals (now part of Jazz Pharmaceuticals) and Canopy Growth focusing on similar areas, although Raphael is focusing on different indications.
• The company's research collaboration with Rambam Health Care Campus is similar to other biotech companies that partner with academic institutions for research and development.

Stakeholder Impact

• Shareholders are at risk due to the company's financial instability and need for additional funding.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company fails to secure additional financing.
• Customers (potential patients) may benefit from the company's research and development efforts if successful, but there is no guarantee of product availability.
• Suppliers and creditors may face risks if the company's financial situation deteriorates further.

Next Steps

• The company will continue its proof-of-concept clinical trial for its RA product candidate.
• The company will continue to conduct pre-clinical research to refine its formulas.
• The company will seek additional financing to fund its operations.
• The company will continue to work towards obtaining regulatory approvals for its product candidates.

Key Dates

Keywords

Pharmaceutical, Cannabinoids, Research and Development, Clinical Trials, Rheumatoid Arthritis, COVID-19, CBD, Cannabigerol, Rambam Health Care Campus, FDA, EMA